Home > Boards > US OTC > Medical - Drugs > Elite Pharmaceuticals (ELTP)

I am an investor not a trader.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
no2koolaid Member Profile
 
Followed By 79
Posts 5,073
Boards Moderated 0
Alias Born 10/06/11
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/2/2021 6:16:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/2/2021 6:14:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/15/2021 5:31:18 PM
Elite Pharmaceuticals reports FQ2 results Seeking Alpha - 11/15/2021 4:51:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:12:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 5:29:36 PM
Elite Pharmaceuticals reports Q1 results Seeking Alpha - 8/16/2021 5:05:15 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2021 4:22:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2021 5:01:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 6:37:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 6:31:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 6:21:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2021 5:16:46 PM
Elite Pharmaceuticals reports FY results Seeking Alpha - 6/14/2021 5:16:14 PM
Annual Report (10-k) Edgar (US Regulatory) - 6/14/2021 5:01:25 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/19/2021 1:29:31 PM
Elite Pharmaceuticals enters exclusive distribution agreement with Prasco Seeking Alpha - 5/4/2021 10:32:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:02:41 PM
Elite Pharmaceuticals names Marc Bregman as chief financial officer Seeking Alpha - 4/29/2021 8:56:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 6:16:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/16/2021 5:04:10 PM
Elite Pharmaceuticals reports FQ3 results Seeking Alpha - 2/16/2021 4:41:50 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/16/2021 4:23:16 PM
no2koolaid   Tuesday, 10/20/15 09:53:19 AM
Re: Drugdoctor post# 167277
Post # of 362910 
I am an investor not a trader. Still, I pay attention to the share prices and there seems to be an inordinate focus on the Elite’s p/s, as if the “wild swings” from 21 cents to 26 cents and back is reflective of anything more than smoke and mirror magic. What is disingenuous is the argument that this somehow reflects the value of Elite and that, since it is stuck in a trading channel, it somehow negates the science. Specifically that would be the science that has led to the patents and successful trials, as well as the P-3 for which results are pending. For those who are truly confused, allow me to offer the following…

Analysts have commented on the current downturn in pharma stocks and suggested the pullback has been exacerbated by those engaged in high frequency trading and who focus on chart patterns, not fundamentals. The problem is that, while the chart patterns in the sector do not look good, many of the companies are strong financially and their science is sound. (Their chart analysis may reflect the “Texas Sharpshooters Fallacy” https://en.wikipedia.org/wiki/Texas_sharpshooter_fallacy) Then there is the link below that supports the argument that short-term price news is of greatest importance to traders, while it only matters to investors on two occasions; when they buy and when they sell. The link is a good read and I would not insult anyone by quoting what they can read for themselves…

http://stocks.about.com/od/evaluatingstocks/a/2013-08-07-Stock-Value-And-Price-Are-Not-The-Same.htm


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences